MediTox s.r.o.


The project aims at developing novel and effective gene-based vaccines activating immune response by means of in vivo electroporation mediated gene transfer (EGT).

Participating countries: Austria, Czech Republic, Denmark, Italy

MediTox s.r.o. was a member of Consortium of the project Center for Development of Original Drugs (CDOD) which in its strategic plan develops traditionally successful fields of Czech medical science and research.

The mission of CDOD project was commercialization and practical application of results of the basic research in the area of development of original drugs.

Following indications were investigated:

  • inflammatory disease, namely ulcerous colitis and other diseases of the alimentary tract (2 projects)
  • neuro-degenerative and psychiatric diseases (1 project)
  • neoplastic diseases (5 projects)
  • treatment of obesity (1 project)

Currently MediTox became a member of consortium of FLUniversal project – Intranasal, rapid acting universal influenza vaccine

Members of the consortium:

  • Vivaldi Biosciences AG (Austria)
  • Academisch Ziekenhuis Leiden (The Netherlands)
  • Statens Serum Institut (Denmark)
  • VisMederi SRL (Italy)
  • Centre for Human Drug Research (The Netherlands)
  • MediTox s.r.o. (Czech Republic)
  • Medicine and Healthcare products Regulatory Agency (UK)
  • InnovaTeknea (Hungary)